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Abstract
Background: Myxopapillary ependymomas (MPE) occur in the filum terminale of the spinal cord,
but also present in extra-spinal locations such as subcutaneous tissue and brain. They are slow
growing grade I gliomas. Areas of solid growth pattern with aggregates of cells with "epithelioid
morphology" seen in MPE can mimic metastatic carcinoma. The presence of occasional cells with
clear cytoplasm and morphology can resemble Chordoma. Diagnosis can be missed due to these
morphological similarities, which could affect patient management and hence, long term survival.
Case presentation: We describe two cases of MPE with cytokeratin (AE1 AE3, CAM 5.2,
Cytokeratin 7 and cytokeratin 20) expression.
Conclusion: MPE can be positive for Cytokeratins (CAM 5.2, AE1 AE3, CK7) and focally for EMA,
which could be misdiagnosed as metastatic carcinoma. In cases demonstrating epithelioid and clear
cell morphology, the diagnosis of MPE should be made in conjunction with histology, proper
immunohistochemical profile which includes co-expression of GFAP, S-100 protein and epithelial
markers, radiologic findings and site. It is important to be aware of the cytokeratin profile in MPE
to avoid erroneous diagnosis with other tumour entities.
Background
Myxopapillary ependymomas (MPE) generally occur in
the filum terminale of the spinal cord, however, they have
been described in extra-spinal locations such as subcuta-
neous tissue [1] and brain [2]. They are slow growing gli-
omas corresponding to WHO grade I [3]. The classical
morphology shows papillae embedded in a myxoid/
mucoid background. Each papilla contains a central
fibrovascular core and is lined by cuboidal to elongated
cells, occasionally showing clear cytoplasm. Microcysts
are also present. The myxoid background contains both
neutral and acidic mucopolysaccharides. Prognosis
depends on the completeness of excision [4]. However,
areas of solid growth pattern with aggregates of cells with
"epithelioid morphology" can also be encountered which
can mimic metastatic carcinoma. In addition, the pres-
ence of cells with clear cytoplasm can also be mistaken for
chordoma. Diagnosis is easily missed due to these mor-
phological similarities, which could affect patient man-
agement and hence, long term survival. A good number of
studies have reported the immunophenotype of MPE and
differential diagnosis of MPE aided by immunohisto-
chemical stains [5-7]. Several studies have reported
absence of cytokeratin expression in MPE [8-10].
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Case presentation
We describe two cases of MPE with cytokeratin expression.
Two female patients, aged 46 and 72 years respectively
presented with low back pain. Magnetic resonance imag-
ing (MRI) of the spine indicated the presence of a large
intra spinal mass in the central canal extending from L3–
L5 in the former patient and a tumour attached to filum
terminale in the latter. Both underwent neurosurgical
removal of the tumor.
Pathological findings
Microscopic examination of the tissue obtained showed
the classical morphological features of MPE with forma-
tion of pseudopapillae and pseudorosettes embedded in a
myxoid stroma. The cells, which made up the pseudoro-
settes, had epithelioid morphology with occasional cells
showing clear cytoplasm (figure 1). In addition, cribri-
form areas (figure 2), solid sheets and cords of cells resem-
bling a carcinoma were also present (figure 3). The
differential diagnosis was, MPE, metastatic carcinoma and
chordoma.
Immunohistochemically, the neoplastic cells showed
strong, diffuse positive reaction with S-100 protein (figure
4a) and glial fibrillary acidic protein (GFAP) (figure 4b),
indicating the glial nature of the lesion. The tumour cells
in both cases showed strong positivity for cytokeratin
markers, AE1AE3 (figure 5a), CAM 5.2 (figure 5b) and
focally for cytokeratin 7. Both cases demonstrated a low
proliferative index (< 2%) with Ki-67. The neoplastic cells
were negative for cytokeratin 20, NSE, synaptophysin and
neurofilament. Epithelial membrane antigen (EMA)
focally stained luminal tips of occasional tumor cells. His-
tochemically, areas of mucoid degeneration were positive
for alcian blue and periodic-acid-schiff (PAS) stains.
Discussion
MPE is a glial tumour occurring almost exclusively in the
region of the cauda equina and considered to be one of
the most frequent primary tumours to occur in this loca-
tion [3,11]. MPE was first described as a separate entity by
Kernohan in 1931 [11] with isolated case reports subse-
quently appearing in the literature [[12]&[13]]. The clini-
cal presentation depends on the location of the tumour.
The majority of cauda equina and filum terminale
tumours present with low back pain due to nerve root
compression similar to our cases. Lower limb weakness
MPE with areas of epithelioid morphology with occasional  cytoplasmic clearing Figure 1
MPE with areas of epithelioid morphology with occa-
sional cytoplasmic clearing. ×200; H&E.
 
MPE with areas showing a cribriform pattern of cells resem- bling a carcinoma Figure 2
MPE with areas showing a cribriform pattern of cells 
resembling a carcinoma. ×400; H&E.
 
MPE demonstrating solid sheets and cords of cells Figure 3
MPE demonstrating solid sheets and cords of cells. 
×200; H&E.
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and sphincter dysfunction are the two other common
clinical manifestations. Intramedullary MPE arise from
the ependymal lined cells of the filum terminale. The pro-
posed histogenesis of extramedullary MPE in this location
is the presence of ependymal rest of the neural tube dur-
ing canalization and retrogressive differentiation [14,15]
or from ectopic ependymal cell [16]. Recent study has sug-
gested that radial glia is the cell of origin of ependymoma
[17,18].
The classic morphology is easily recognizable, comprising
multiple papillae covered by flattened to cuboidal cells
embedded in a myxoid stroma and forming pseudoro-
settes. However, there are cases where the tumour obtains
a solid growth pattern with aggregates of cells with "epi-
thelial morphology" which in addition may show clearing
of the cytoplasm. In such instances, metastatic carcinomas
of renal origin and chordoma have to be ruled out by ade-
quate clinical history and immunohistochemical stains.
It is well known that MPE stain positive with GFAP and S-
100 protein. Cytokeratin positivity in MPE has been a sub-
ject of controversy with few cases reported showing posi-
tive cytokeratin expression in MPE [5,19,20]. Both our
cases were positive for CAM5.2, AE1AE3, EMA and CK7
but negative for CK20.
Morphological variations in MPE can resemble metastatic
carcinoma. An erroneous diagnosis may subject the
patients to unnecessary metastatic work-up and addi-
tional adjuvant therapy. In addition, one should also con-
sider the psychological implication of diagnosing a
carcinoma. MPE has a better prognosis with tendency for
late recurrence, except for some cases with aggressive
behavior and seeding to the CNS [21]. MPE with clear cell
changes and positive staining for S-100 protein, keratins
and EMA can be misdiagnosed as chordoma, the latter
being positive for Cytokeratin markers and S-100 protein
but negative for GFAP. Although, metastatic carcinomas
are positive for cytokeratins, these are consistently nega-
tive for GFAP.
MPE can be positive for Cytokeratins (CAM 5.2, AE1 AE3,
and CK7) and focally for EMA. Given the similarities in
morphology between metastatic carcinoma, chordoma
and MPE, the diagnosis of MPE should be made in con-
junction with clinical history including tumour location,
immunohistochemical profile (co-expression of GFAP, S-
100 protein and epithelial markers in MPE) and radiolog-
ical findings. The recommended panel should include
Cytokeratins (positive in MPE, metastatic carcinoma and
chordoma), GFAP (positive in MPE and negative in meta-
static carcinoma and chordoma), and S-100 protein (pos-
itive in MPE, chordoma but negative in most metastatic
carcinomas).
The majority of MPE are slow growing gliomas with a ten-
dency for local recurrence. Prognosis depends on com-
plete surgical resection of the tumor. The risk of metastasis
is very low and rare. The overall prognosis of MPE is much
better than metastatic carcinoma and the latter has to be
ruled out as they can have similar morphological features.
In conclusion, we reemphasize the importance of using a
panel of immunohistochemical stains to differentiate
between MPE and other tumour entities to avoid misdiag-
nosis.
A: Positive S-100 protein stain in the neoplastic cells indicat- ing glial nature of the lesion Figure 4
A: Positive S-100 protein stain in the neoplastic cells 
indicating glial nature of the lesion. ×200. 4B: GFAP 
positivity in the neoplastic cells. ×200.
   
Positive epithelial markers; AE1AE3 (A) and CAM5 Figure 5
Positive epithelial markers; AE1AE3 (A) and CAM5.2 
(B) in the neoplastic cells.
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